Hospira Inc 

HSP:NYSE

LastChange / % ChangeDividend YieldVolume
56.29 0.0900   0.16%0.00%833,696

Market data is delayed by at least 20 minutes.

Exclusive Features

When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes.

For full analysis details, Log In with Scottrade or you can:
  •  
    Advanced Charts

  •  
    Embed Chart

    Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

  • 1 Day
  • 5 Day
  • 6 Mo
  • 1 Yr
  • 5 Yr
 
 
 

Latest News Headlines for Hospira Inc

Hospira (HSP) Crosses Pivot Point Support at $54.78
7 days 10 hours 12 minutes ago - Comtex SmarTrend(R)
SmarTrend has detected shares of Hospira (NYSE:HSP) have bearishly opened below the pivot of $55.07 today and have reached the first level of support of $54.78. Should the shares continue to fall, we are monitoring the next support pivots of $54.37 and $53.67. Also, the shares are currently trading below the 50-day moving average of $57.03 and below the 200-day moving average of $55.52.
View more recent headlines
 
 
 
 
 
 
More Filings

Latest Annual and Quarterly SEC Filings

10-K
February 18, 2010
This report contains detailed information about the company's business finances and management.
10-Q
October 26, 2010
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
 
 
 
Company Background
Hospira, Inc. is a specialty pharmaceutical and medication delivery company that develops, manufactures and markets products. Its portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Its portfolio of products is used by hospitals, clinics, home healthcare providers and long-term care facilities. It has three segments: Americas; Europe, Middle East and Africa (EMEA), and Asia Pacific. The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa, and the APAC segment includes Asia, Japan, Australia and New Zealand. In October 2009, Halcygen Pharmaceuticals Limited acquired Mayne Pharma International Pty Ltd from Hospira Australia Pty Ltd. In December 2009, it acquired TheraDoc, Inc. In March 2010, Hospira, Inc. completed the acquisition of the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd.
Bid/Size
-- / --
Ask/Size
-- / --
Price Open
56.16
Previous Close
56.20
Day High
56.30
Day Low
55.99
52wk High/Date
60.49 / 11/4/2010
52wk Low/Date
47.48 / 2/5/2010
Beta
0.68
Market Capitalization
9.40B
Shares Outstanding
167.08M
Volatility Avg
21.89
Avg Vol(10 day)
1.37M
P/E Ratio
24.1x
EPS (TTM)
2.33
Annualized Rate
-- / --
Yield
0.00%
Dividend Announcement
--
Ex-Date
--
Date of Record
--
Payable
0.00 - --
Payable Date
--
Last Trade as of 1/14/2011 4:03 PM ET

Exclusive Content

When you open an account with Scottrade, you will get premium content on the News & Content page, including:

  • Standard & Poor's News and Commentary
  • Dow Jones News
  • Briefing News and Commentary
  • Market Edge On the Edge Commentary
For full analysis details, Log In with Scottrade or you can:
 
 
 

HSP Hospira Inc vs. Peers

Peers 
HSP
Hospira Inc
1.08%
BAX
Baxter International Inc.
-0.61%
CFN
CareFusion Corporation
4.44%
HSP
Hospira Inc
0.00%
BAX
Baxter International Inc.
2.46%
CFN
CareFusion Corporation
--
HSP
Hospira Inc
0.16%
BAX
Baxter International Inc.
-0.08%
CFN
CareFusion Corporation
1.32%
Compare these stocks
 
 
 
© 2011 Scottrade

Brokerage Products and Services offered by Scottrade, Inc. - Member FINRA and SIPC

Online market and limit stock trades are just $7 for stocks priced $1 and above.

Any specific securities, or types of securities, used as examples are for demonstration purposes only. No information on this Web site should be considered a recommendation or None of the information provided should be considered a recommendation or solicitation to invest in, or liquidate, a particular security or type of security.

Investors should consider the investment objectives, risks, and charges and expenses of a mutual fund carefully before investing. A mutual fund's prospectus contains this and other information about the mutual fund. Prospectuses are available through our trading site or through a Scottrade Branch Office. The prospectus should be read carefully before investing. No transaction fee (NTF) funds are subject to the terms and conditions of the NTF funds program. Scottrade is compensated by the funds participating in the NTF program through recordkeeping, shareholder, or SEC 12b-1 fees.

Investors should consider the investment objectives, charges, expense, and unique risk profile of an Exchange Traded Fund (ETF) carefully before investing. Leveraged and Inverse ETFs may not be suitable for long-term investors and may increase exposure to volatility through the use of leverage, short sales of securities, derivatives and other complex investment strategies. A prospectus contains this and other information about the ETF and should be obtained from the issuer. The prospectus should be read carefully before investing.

Margin trading involves interest charges and risks, including the potential to lose more than deposited, or the need to deposit additional collateral in a falling market. Margin Disclosure Statement (PDF) is available for download, or it is available at one of our branch offices. It contains information on our lending policies, interest charges, and the risks associated with margin accounts.

Options involve risk and are not suitable for all investors. Detailed information on our policies and the risks associated with options can be found in the Scottrade Options Application and Agreement, Brokerage Account Agreement, and by downloading the Characteristics and Risks of Standardized Options and Supplements (PDF) from The Options Clearing Corporation, or by requesting a copy from your local branch office. Supporting documentation for any claims will be supplied upon request.

Market volatility, volume, and system availability may impact account access and trade execution.

Testimonials may not be representative of the experience of other clients and are no guarantee of future performance or success.